2Slamler J , Wentworth D, Neaton J D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) [J]. JAMA, 1986,256 (20) : 2823 -2828.
3Castelli W P, Garrison R J, Wilson PwF, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framing ham Study [ J ]. JAMA, 1986, 256(20) : 2835-2838.
4Frick M H, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle aged men with dislipidemia. Safetyof treatment, chages in risk factors, and incidence of coronary heart disease [J]. N Engl J Med, 1987,317 (20) : 1237-1245.
5Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel Ⅱ) [J]. JAMA, 1993, 269(23):3015-3023.
6Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in Adults. The Expert Panel [J]. Arch Intern Med, 1998, 148 (1): 36-69.
7Sniderman A D, Pedersen T, Kjekshus J. Putting low density lipoproteins at a center stage in atherogenesis [J]. Am J Cardiol, 1997, 79( 1 ) :64-67.
8Kaplan I V, Levinson S S. Apolipoprotein snd related testing as markersfor coronary disease [J]. Lab Med Int, 1998, 15 ( 1 ) : 12 - 14.
9Michaeld, Patricke, Evanas, et al. Comparison of effects on lowdensity lipoprotein and cholesterol with rosuvastatin versusatorvastatin in patients with type Ⅱ a or Ⅱ b hypercholesterolemia [J]. J Am Cardiol, 2002,89(2) : 268-275.
10Shwartz G G, Bolognese M A, Tremblay B P, et al. Efficacy and safety of rosuvastatin and atorvastin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial [ J ]. Am Heart J, 2004,148 ( 1 ) : e4.
